Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy
Identifieur interne : 001333 ( France/Analysis ); précédent : 001332; suivant : 001334Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy
Auteurs : A. A. Fauser [Allemagne] ; B. Duclos [France] ; A. Chemaissani [Allemagne] ; A. Del Favero [Italie] ; F. Cognetti [Italie] ; E. Diaz-Rubio [Espagne] ; H. Cortes-Funes [Espagne] ; P. F. Conte [Italie] ; H. Dressler [Allemagne]Source :
- European Journal of Cancer [ 0959-8049 ] ; 1996.
Abstract
This multicentre, randomised, double-blind study was designed to compare the anti-emetic efficacy and safety of single oral doses of dolasetron mesilate with that of the approved oral, multiple-dose regimen of ondansetron in 399 cancer patients receiving moderately emetogenic chemotherapy. Single oral doses of 25, 50, 100 or 200 mg of dolasetron mesilate were administered 1 h prior to the initiation of moderately emetogenic chemotherapy. Multiple doses of ondansetron (8 mg × 3 or 8 mg × 4) capsules, or matching placebo for patients randomised to dolasetron, were given 1.5 h before and 6.5, 14.5 and 22.5 h after the start of chemotherapy (total dose = 32 mg). Efficacy was evaluated for 24 h after the initiation of chemotherapy. The most frequently used moderately emetogenic chemotherapeutic agents included cyclophosphamide, doxorubicin and carboplatin (28.4, 23.1 and 20.6% of patients, respectively). A statistically significant (P < 0.001) linear dose-response relationship was observed over the entire dolasetron dosage range for all efficacy parameters. Complete response rates were 45.0, 49.4, 60.5 and 76.3% for 25, 50, 100 and 200 mg dolasetron mesilate, respectively, and 72.3% of ondansetron patients. A single oral 200 mg dolasetron mesilate dose was therapeutically equivalent to ondansetron for all efficacy parameters and patient satisfaction was high. Overall, there were no significant differences in the incidence of adverse events between any of the dolasetron mesilate doses, or between dolasetron and ondansetron. Headache was most frequently reported (approximately 15% for each drug). No clinically important changes in vital signs or clinical laboratory parameters were observed with either drug. In conclusion, a single oral 200 mg dolasetron mesilate dose was therapeutically equivalent to multiple-dose ondansetron in the prevention of emesis and nausea following moderately emetogenic chemotherapy. Copyright © 1996 Elsevier Science Ltd
Url:
DOI: 10.1016/0959-8049(96)00132-3
Affiliations:
- Allemagne, Espagne, France, Italie
- Alsace (région administrative), Communauté de Madrid, District de Cologne, Grand Est, Latium, Rhénanie-du-Nord-Westphalie, Toscane
- Cologne, Madrid, Pise, Rome, Strasbourg
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001646
- to stream Istex, to step Curation: 001646
- to stream Istex, to step Checkpoint: 000D64
- to stream Main, to step Merge: 001F06
- to stream Main, to step Curation: 001E51
- to stream Main, to step Exploration: 001E51
- to stream France, to step Extraction: 001333
Links to Exploration step
ISTEX:A736C548FAB254C42AA259E5696F42EF32812F3ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy</title><author><name sortKey="Fauser, A A" sort="Fauser, A A" uniqKey="Fauser A" first="A. A." last="Fauser">A. A. Fauser</name></author><author><name sortKey="Duclos, B" sort="Duclos, B" uniqKey="Duclos B" first="B." last="Duclos">B. Duclos</name></author><author><name sortKey="Chemaissani, A" sort="Chemaissani, A" uniqKey="Chemaissani A" first="A." last="Chemaissani">A. Chemaissani</name></author><author><name sortKey="Del Favero, A" sort="Del Favero, A" uniqKey="Del Favero A" first="A." last="Del Favero">A. Del Favero</name></author><author><name sortKey="Cognetti, F" sort="Cognetti, F" uniqKey="Cognetti F" first="F." last="Cognetti">F. Cognetti</name></author><author><name sortKey="Diaz Rubio, E" sort="Diaz Rubio, E" uniqKey="Diaz Rubio E" first="E." last="Diaz-Rubio">E. Diaz-Rubio</name></author><author><name sortKey="Cortes Funes, H" sort="Cortes Funes, H" uniqKey="Cortes Funes H" first="H." last="Cortes-Funes">H. Cortes-Funes</name></author><author><name sortKey="Conte, P F" sort="Conte, P F" uniqKey="Conte P" first="P. F." last="Conte">P. F. Conte</name></author><author><name sortKey="Dressler, H" sort="Dressler, H" uniqKey="Dressler H" first="H." last="Dressler">H. Dressler</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A736C548FAB254C42AA259E5696F42EF32812F3A</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1016/0959-8049(96)00132-3</idno><idno type="url">https://api.istex.fr/document/A736C548FAB254C42AA259E5696F42EF32812F3A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001646</idno><idno type="wicri:Area/Istex/Curation">001646</idno><idno type="wicri:Area/Istex/Checkpoint">000D64</idno><idno type="wicri:doubleKey">0959-8049:1996:Fauser A:therapeutic:equivalence:of</idno><idno type="wicri:Area/Main/Merge">001F06</idno><idno type="wicri:Area/Main/Curation">001E51</idno><idno type="wicri:Area/Main/Exploration">001E51</idno><idno type="wicri:Area/France/Extraction">001333</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy</title><author><name sortKey="Fauser, A A" sort="Fauser, A A" uniqKey="Fauser A" first="A. A." last="Fauser">A. A. Fauser</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Klinik für Hämatologic/Onkologic and Knochenmarktransplantation, Dr. -Ottmar-Kohler-Str.2, D-55743 Idar Oberstein</wicri:regionArea><wicri:noRegion>55743 Idar Oberstein</wicri:noRegion><wicri:noRegion>D-55743 Idar Oberstein</wicri:noRegion></affiliation></author><author><name sortKey="Duclos, B" sort="Duclos, B" uniqKey="Duclos B" first="B." last="Duclos">B. Duclos</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Les Hopitaux Universitaires de Strasbourg, Hopital Civil, 1, place de l'Hopital, 67091 Strasbourg Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author><author><name sortKey="Chemaissani, A" sort="Chemaissani, A" uniqKey="Chemaissani A" first="A." last="Chemaissani">A. Chemaissani</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Kliniken der Stadt Köln, Krankenhaus Merheim, Lungenklinik 51058 Köln</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Cologne</settlement></placeName></affiliation></author><author><name sortKey="Del Favero, A" sort="Del Favero, A" uniqKey="Del Favero A" first="A." last="Del Favero">A. Del Favero</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Universita Degli Studi Di Perugia, Istituto Di Medicina Interna, Policlinico Monteluce, 06100 Perugia</wicri:regionArea><wicri:noRegion>06100 Perugia</wicri:noRegion></affiliation></author><author><name sortKey="Cognetti, F" sort="Cognetti, F" uniqKey="Cognetti F" first="F." last="Cognetti">F. Cognetti</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Instituto Regina Elena, Oncologia Medica, Viale Regina Elena 291, 00161 Roma</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Diaz Rubio, E" sort="Diaz Rubio, E" uniqKey="Diaz Rubio E" first="E." last="Diaz-Rubio">E. Diaz-Rubio</name><affiliation wicri:level="2"><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario de San Carlos, 28040 Madrid</wicri:regionArea><placeName><region nuts="2" type="communauté">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Cortes Funes, H" sort="Cortes Funes, H" uniqKey="Cortes Funes H" first="H." last="Cortes-Funes">H. Cortes-Funes</name><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario, 12 De Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Conte, P F" sort="Conte, P F" uniqKey="Conte P" first="P. F." last="Conte">P. F. Conte</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Unita Sanitaria Locale n. 12-Area Pisana, Ospedale S. Chiara-Pisa, U.O. Oncologia Medica, Via Roma, 67-56100 Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region nuts="2">Toscane</region></placeName></affiliation></author><author><name sortKey="Dressler, H" sort="Dressler, H" uniqKey="Dressler H" first="H." last="Dressler">H. Dressler</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Praktischer Arzt, Nordenstadter Str. 6, D-65719 Hofheim-Wallau</wicri:regionArea><wicri:noRegion>65719 Hofheim-Wallau</wicri:noRegion><wicri:noRegion>D-65719 Hofheim-Wallau</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Cancer</title><title level="j" type="abbrev">EJC</title><idno type="ISSN">0959-8049</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1996">1996</date><biblScope unit="volume">32</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1523">1523</biblScope><biblScope unit="page" to="1529">1529</biblScope></imprint><idno type="ISSN">0959-8049</idno></series><idno type="istex">A736C548FAB254C42AA259E5696F42EF32812F3A</idno><idno type="DOI">10.1016/0959-8049(96)00132-3</idno><idno type="PII">0959-8049(96)00132-3</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0959-8049</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This multicentre, randomised, double-blind study was designed to compare the anti-emetic efficacy and safety of single oral doses of dolasetron mesilate with that of the approved oral, multiple-dose regimen of ondansetron in 399 cancer patients receiving moderately emetogenic chemotherapy. Single oral doses of 25, 50, 100 or 200 mg of dolasetron mesilate were administered 1 h prior to the initiation of moderately emetogenic chemotherapy. Multiple doses of ondansetron (8 mg × 3 or 8 mg × 4) capsules, or matching placebo for patients randomised to dolasetron, were given 1.5 h before and 6.5, 14.5 and 22.5 h after the start of chemotherapy (total dose = 32 mg). Efficacy was evaluated for 24 h after the initiation of chemotherapy. The most frequently used moderately emetogenic chemotherapeutic agents included cyclophosphamide, doxorubicin and carboplatin (28.4, 23.1 and 20.6% of patients, respectively). A statistically significant (P < 0.001) linear dose-response relationship was observed over the entire dolasetron dosage range for all efficacy parameters. Complete response rates were 45.0, 49.4, 60.5 and 76.3% for 25, 50, 100 and 200 mg dolasetron mesilate, respectively, and 72.3% of ondansetron patients. A single oral 200 mg dolasetron mesilate dose was therapeutically equivalent to ondansetron for all efficacy parameters and patient satisfaction was high. Overall, there were no significant differences in the incidence of adverse events between any of the dolasetron mesilate doses, or between dolasetron and ondansetron. Headache was most frequently reported (approximately 15% for each drug). No clinically important changes in vital signs or clinical laboratory parameters were observed with either drug. In conclusion, a single oral 200 mg dolasetron mesilate dose was therapeutically equivalent to multiple-dose ondansetron in the prevention of emesis and nausea following moderately emetogenic chemotherapy. Copyright © 1996 Elsevier Science Ltd</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Espagne</li><li>France</li><li>Italie</li></country><region><li>Alsace (région administrative)</li><li>Communauté de Madrid</li><li>District de Cologne</li><li>Grand Est</li><li>Latium</li><li>Rhénanie-du-Nord-Westphalie</li><li>Toscane</li></region><settlement><li>Cologne</li><li>Madrid</li><li>Pise</li><li>Rome</li><li>Strasbourg</li></settlement></list><tree><country name="Allemagne"><noRegion><name sortKey="Fauser, A A" sort="Fauser, A A" uniqKey="Fauser A" first="A. A." last="Fauser">A. A. Fauser</name></noRegion><name sortKey="Chemaissani, A" sort="Chemaissani, A" uniqKey="Chemaissani A" first="A." last="Chemaissani">A. Chemaissani</name><name sortKey="Dressler, H" sort="Dressler, H" uniqKey="Dressler H" first="H." last="Dressler">H. Dressler</name></country><country name="France"><region name="Grand Est"><name sortKey="Duclos, B" sort="Duclos, B" uniqKey="Duclos B" first="B." last="Duclos">B. Duclos</name></region></country><country name="Italie"><noRegion><name sortKey="Del Favero, A" sort="Del Favero, A" uniqKey="Del Favero A" first="A." last="Del Favero">A. Del Favero</name></noRegion><name sortKey="Cognetti, F" sort="Cognetti, F" uniqKey="Cognetti F" first="F." last="Cognetti">F. Cognetti</name><name sortKey="Conte, P F" sort="Conte, P F" uniqKey="Conte P" first="P. F." last="Conte">P. F. Conte</name></country><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Diaz Rubio, E" sort="Diaz Rubio, E" uniqKey="Diaz Rubio E" first="E." last="Diaz-Rubio">E. Diaz-Rubio</name></region><name sortKey="Cortes Funes, H" sort="Cortes Funes, H" uniqKey="Cortes Funes H" first="H." last="Cortes-Funes">H. Cortes-Funes</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001333 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 001333 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/France
|area= LeHavreV1
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:A736C548FAB254C42AA259E5696F42EF32812F3A
|texte= Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy
}}
| This area was generated with Dilib version V0.6.25. |  |